Developer docs
API playgroundTry for free, no card

Search company profiles

KSL Diagnostics

Full company profile

uuid000oe7m

Namestring
KSL Diagnostics
Legal namestring
KSL Diagnostics, Inc.
Websiteurl
ksldx.com
Company typeenum
Private
Founded yearint
2018
Descriptiontext

KSL Diagnostics, Inc. is a privately held, CAP-accredited and CLIA-certified national reference laboratory headquartered in Buffalo, New York, operating as a wholly-owned subsidiary of KSL Biomedical, Inc. The company provides specialized clinical diagnostic testing across four service lines: oncology cytogenetics (FISH panels for AML, MDS, MPN, CLL, multiple myeloma, ALL, lymphoma, and triple-hit lymphoma, plus conventional karyotyping), diagnostic immunology (HNA, Fungitell®, hepatitis serologies, Sjögren's disease antibodies, and the proprietary COVID-19 Immune Index™), transplant immunology (HLA typing, antibody screening, and deceased/living donor evaluation with 4-hour STAT turnaround), and biochemical/molecular genetics (disaccharidases activity panel). The test menu is built on conventional molecular and cytogenetic platforms (FISH, real-time PCR, flow cytometry, Luminex, gel agglutination, ELISA) and the company holds clinical laboratory permits in New York, Pennsylvania, California, Maryland, and Rhode Island, plus ASHI accreditation and ISO 13485/15189 certifications for affiliated KSL Biomedical manufacturing and laboratory facilities.

The company generates revenue on a fee-for-service, per-test basis billed to healthcare providers under CPT codes (e.g., AML Panel 88271x16, 88275x8; HLA Antibody Screen 86832/86833), with prices not publicly disclosed. Its go-to-market is consultative, sales-led enterprise field sales targeting oncologists, hematologists, pathologists, cytogenetic laboratories, and solid-organ transplant programs, with named anchor relationships at Kaleida Health facilities and Erie County Medical Center. A second channel serves consumers directly through 4 permanent Western New York testing sites and a 25+ partner network of independent pharmacies and urgent care centers, used initially for COVID-19 testing and vaccination pop-ups (Walden Galleria, Rainbow Bridge) that delivered over 500,000 pandemic-era tests. KSL is the central laboratory for ImCare Biotech's FDA Breakthrough Device Designation Seravue® LC-SPIK hepatocellular carcinoma assay and is preparing LDT panel launches in 2026-2027, signaling a planned expansion into solid tumor diagnostics.

Short descriptiontext

KSL Diagnostics is a CAP-accredited, CLIA-certified reference laboratory in Buffalo, NY, providing specialized cytogenetic, molecular, and immunology diagnostic testing to healthcare providers, transplant programs, and physician practices across five US-licensed states.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBuffalo, United States
HQ citystring
Buffalo
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical reference laboratory, cytogenetic diagnostic testing, molecular diagnostic services, transplant immunology testing, FISH probe panels
Industry6 codes
PRIMARYHLAFAMAJ
Reference & Esoteric Testing Laboratories
SECONDARYHLAAALAN
Laboratory Developed Tests (LDTs) & Specialized Clinical Lab Assays
SECONDARYHLAHAAAI
Genetic, Cytogenetic & Prenatal Screening IVD
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAGAEAB
Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAAALAI
Cytology & Histopathology Diagnostics (IHC, ISH, tissue-based assays)
SECONDARYHLAGADAA
Bioanalytical Testing (PK/ADA/NAb)
NAICS code3 codes
  • Medical Laboratories621511
  • Medical and Diagnostic Laboratories62151
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code2 codes
  • Services-Medical Laboratories8071
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Clinical Reference Laboratory Services
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Clinical Laboratory Testing Services
TypeTransaction Fee
Description

Reference laboratory providing diagnostic testing services for oncology, cytogenetics, molecular diagnostics, diagnostic immunology, transplant immunology, and genetic testing. Revenue generated through billable laboratory tests ordered by healthcare providers.

ksldx.com
2COVID-19 Testing Services
TypeTransaction Fee
Description

COVID-19 testing including RT-PCR (30-minute and 24-hour turnaround) and rapid antigen tests provided at testing sites and pop-up locations. Revenue generated through test fees, insurance billing, and government assistance programs.

ksldx.com
3Specialized Diagnostic Panels
TypeTransaction Fee
Description

Comprehensive disease-specific testing panels (e.g., AML Panel, CLL Panel, MDS Panel) and individual FISH probes offered as discrete laboratory tests billed per CPT code

ksldx.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain
Pricing details1 tier
1Laboratory diagnostic tests billed per test or panel
ModelTransaction based/ take rateBilling cadencePay-as-you-go
Notes

Tests are billed using CPT codes. Examples: AML Panel (88271 x16, 88275 x8), CLL Panel, HLA Antibody Screen (86832, 86833). Specific prices not publicly listed.

ksldx.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1COVID-19 Immune Index™
Description

First-of-its-kind antibody test that detects immune response to COVID-19 and assesses risk of infection if subsequently exposed. Correlates COVID-19 virus neutralization against antibody levels.

ksldx.com
Core offering1 text field

KSL Diagnostics is a national reference laboratory providing clinical diagnostic testing services in cytogenetics (FISH panels for leukemia, lymphoma, and myeloma), molecular oncology, diagnostic immunology, transplant immunology (HLA typing and donor evaluation), biochemical/molecular genetics, and infectious disease (including its proprietary COVID-19 Immune Index™ antibody test). Tests are ordered by healthcare providers and delivered through a CAP-accredited, CLIA-certified laboratory operating 24/7 for STAT testing, with results delivered via the KSL Outreach® secure portal.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 100% virus neutralization at IgG levels of 20 and above in COVID-19 Immune Index testing
+2 more records
Product overview1 text field

KSL Diagnostics is a national reference laboratory offering integrated clinical diagnostic services across four main divisions: Oncology/Cytogenetics (FISH panels for AML, MDS, MPN, CLL, Multiple Myeloma, ALL, Lymphoma, and Triple Hit Lymphoma plus chromosome analysis), Diagnostic Immunology (HNA, Fungitell®, Hepatitis, Sjögren's Disease, and COVID-19 Immune Index™ testing), Transplant Immunology (HLA typing, antibody monitoring, and donor evaluation for solid organ transplantation), and Biochemical/Molecular Genetics (disaccharidases panel). The company operates as a CAP-accredited and CLIA-certified facility providing comprehensive testing menus across oncology, immunology, genetics, and infectious diseases. KSL also serves as the central laboratory for ImCare Biotech's LC-SPIK hepatocellular carcinoma Clinical Trial Assay. Testing services are supported by a secure reporting portal (KSL Outreach®) and the COVID-19 Immune Index™ for immunity assessment.

Product and service22 records
1AML Panel
CategoryOncology Cytogenetics
Description

Comprehensive FISH panel for Acute Myeloid Leukemia covering 8 genetic markers including t(15;17) PML/RARA, inv(16) CBFB, t(8;21) RUNX1T1/RUNX1, and key deletions and translocations; KSL guarantees 24-hour STAT results for PML/RARA. Ordered by hematologists, oncologists, and pathology groups for AML diagnosis, prognosis, and treatment guidance.

2MDS Panel
CategoryOncology Cytogenetics
Description

FISH panel for Myelodysplastic Syndromes covering del(5q)/monosomy 5, del(7q)/monosomy 7, del(20q)/monosomy 20, Trisomy 8, and 11q23.3 KMT2A. Used by hematologists and pathologists for MDS diagnosis and risk stratification.

3MPN Panel
CategoryOncology Cytogenetics
Description

FISH panel for Myeloproliferative Neoplasms detecting PDGFRB and FGFR1 rearrangements and the CML-associated t(9;22) BCR/ABL/ASS translocation. Used to support diagnosis and therapeutic targeting in MPN and CML.

4CLL Panel
CategoryOncology Cytogenetics
Description

FISH panel for Chronic Lymphocytic Leukemia covering 6q23.3 MYB, 11q23.3 ATM, Trisomy 12, t(11;14) CCND1/IGH, del(13q), and 17p13 TP53. Used by hematologists for CLL prognosis and treatment selection.

5Multiple Myeloma (MM) Panel
CategoryOncology Cytogenetics
Description

FISH panel for Multiple Myeloma using CD138+ plasma cell selection, covering CDKN2C/CKS1B, trisomies, RB1, IGH, and TP53 markers; includes an MM Reflex Panel for IgH rearrangement. Used for myeloma risk stratification and disease monitoring.

6ALL Panel
CategoryOncology Cytogenetics
Description

FISH panel for Acute Lymphoblastic Leukemia detecting 8q24.21 MYC, t(9;22) BCR/ABL1, 11q23.3 KMT2A, and 14q32.3 IGH rearrangements. Used to support ALL diagnosis, risk stratification, and targeted therapy decisions.

7Lymphoma Panel
CategoryOncology Cytogenetics
Description

FISH panel for lymphoma detection covering BCL6, MYC, CCND1/IGH, IGH, and IGH/BCL2 translocations. Used by pathologists and oncologists to classify lymphoma subtype.

8Triple Hit Lymphoma FISH Panel
CategoryOncology Cytogenetics
Description

Specialized FISH panel for high-grade B-cell lymphomas detecting concurrent rearrangements of MYC, BCL2, and BCL6 (double/triple-hit lymphomas) using 18q21.3 BCL2, 3q27 BCL6, and 8q24.21 MYC probes. Used for aggressive lymphoma classification and treatment planning.

9Chromosome Analysis (Conventional Karyotype)
CategoryOncology Cytogenetics
Description

Conventional cytogenetic karyotype analysis for hematopoietic malignancies using bone marrow or peripheral blood specimens to detect acquired chromosome abnormalities. Used by hematologists and oncologists alongside FISH panels.

10Human Neutrophil Antibodies (HNA) Test
CategoryDiagnostic Immunology
Description

Bead-based multiplex immunoassay detecting neutrophil antibodies associated with TRALI, SLE, RA, Myasthenia gravis, Felty's syndrome, and drug-induced neutropenia. Used by transfusion medicine services and immunologists.

11Fungitell® (1,3)-Beta-D-Glucan Test
CategoryDiagnostic Immunology
Description

Qualitative ELISA for invasive fungal infections including Candida, Aspergillus, and Pneumocystis, with an optional reflex to titer. Used by infectious disease and immunology clinicians.

12Hepatitis D (Anti-HDV) Antibody Test
CategoryDiagnostic Immunology
Description

Qualitative ELISA for Hepatitis D antibody detection for clinical workup of hepatitis D co-infection.

13Hepatitis E IgG ELISA
CategoryDiagnostic Immunology
Description

Qualitative ELISA for Hepatitis E IgG antibody detection used to evaluate prior exposure or immunity.

14Tissue Specific Antibodies in Early Sjögren's Disease Diagnosis
CategoryDiagnostic Immunology
Description

Immunoassay billed under PLA code 0522U for early detection of Sjögren's Disease-specific tissue antibodies, supporting autoimmune diagnosis and clinical research.

15Disaccharidases Activity Panel
CategoryBiochemical and Molecular Genetics
Description

Quantitative spectrophotometry assay of disaccharidase enzyme activity in small intestine tissue biopsies for diagnosis of gastrointestinal dysfunction and lactose intolerance.

16Deceased Donor Evaluation
CategoryTransplant Immunology
Description

HLA typing and evaluation for deceased organ donors using Real-Time PCR, Flow Cytometry, and Gel Agglutination, with STAT results within 4 hours of receipt. Used by solid-organ transplant programs.

17Living Donor Evaluation
CategoryTransplant Immunology
Description

Preliminary or final HLA typing for living organ donors, including lymphocyte crossmatch with intended recipients. Used by solid-organ and bone marrow transplant programs.

18HLA Antibody Monitoring
CategoryTransplant Immunology
Description

Luminex-based HLA antibody screening and identification for pre- and post-transplant monitoring, with reflex to single antigen testing. Used to detect sensitization and inform transplant timing.

19Solid Organ Transplant Candidate Evaluation
CategoryTransplant Immunology
Description

Comprehensive transplant candidate evaluation combining HLA typing and antibody monitoring using multiple methodologies. Used by transplant centers to evaluate candidates pre-transplant.

20HLA Antibody Screen (Class I and Class II)
CategoryTransplant Immunology
Description

Luminex-based screening for HLA Class I and Class II antibodies implicated in TRALI, transplant rejection, and bone marrow engraftment.

21COVID-19 Immune Index™
CategoryInfectious Disease Diagnostics
Description

First-of-its-kind antibody test that measures IgG titers and correlates results with plaque reduction neutralization test (PRNT) results to assess immune protection. Used by immunocompromised patients, at-risk populations, and clinicians to inform booster timing.

22LC-SPIK (Seravue®) Hepatocellular Carcinoma Test
CategoryOncology Cytogenetics
Description

Clinical Trial Assay for Hepatocellular Carcinoma using the Seravue® ELISA platform to detect the Liver Cancer-Secreted Serine Protease Inhibitor Kazal (LC-SPIK) biomarker, delivered in partnership with ImCare Biotech. Used by oncologists and clinical trial investigators for HCC diagnosis.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

Partnership for hepatocellular carcinoma (HCC) diagnostics using LC-SPIK biomarker. KSL Diagnostics serves as central laboratory for Seravue® Validation Study (NCT06994130). KSL to launch LDT panels for HCC in 2026-2027. ImCare Biotech discovered and developed the LC-SPIK liver cancer biomarker.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

Dr. Lakshmanan Suresh serves as Clinical Professor at SUNY Buffalo. Multiple research collaborations with investigators throughout the world. KSL team members maintain academic affiliations and collaborative research programs.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-05-01
Description

Research partnership with UB on SARS-CoV-2 antibody studies leading to COVID-19 Immune Index™ development. Collaborated with Dr. Amy Jacobs on plaque reduction neutralization testing (PRNT) correlation studies using UB's Biosafety Level 3 containment facility. Study funded by UB Center for Advanced Technology in Big Data and Health Sciences (UB CAT).

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-05-01
Description

UB CAT, a program of Empire State Development's Division of Science, Technology and Innovation (NYSTAR), supports university-industry collaborations. Funded research on COVID-19 antibody correlation studies and supported commercialization of COVID-19 Immune Index™.

Strategic tierSecondaryTypeChannel Partner/ Reseller/ DistributorAnnounced on2021-11-01
Description

WNY family-owned community pharmacy since 1968 administers COVID-19 vaccinations at KSL's Walden Galleria pop-up testing site. KSL provides testing infrastructure while pharmacy provides vaccination administration services.

6Walden Galleria
Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2021-11-01
Description

Shopping mall location hosting KSL Diagnostics pop-up COVID-19 testing and vaccination site on second floor next to Macy's, serving holiday shoppers and Canadian travelers.

ksldx.com
7Rainbow Bridge Niagara Falls
Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2021-11-01
Description

Mobile COVID-19 testing site at Rainbow Bridge corner (1st and Niagara Streets) serving cross-border travelers requiring PCR tests for Canadian entry.

ksldx.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

International reference lab operator with a sizable U.S. footprint in clinical and specialty testing. Comparable as a multi-state reference lab competing in esoteric and specialty diagnostics.

TypeDirect peer
Description

Genetic/molecular diagnostics company focused on hereditary cancer and broader genetic testing, serving oncologists and clinicians. Comparable to KSL's genetic testing and molecular oncology capabilities and customer overlap.

TypeDirect peer
Description

Molecular diagnostics company with specialty oncology and transplant-related testing (e.g., Signatera, Prospera). Comparable in its oncology-focused specialty menu and its positioning with cancer centers and transplant programs.

TypeBroad incumbent
Description

Largest U.S. clinical laboratory with national logistics, broad specialty menu, and dominant payor contracts. Competes with KSL on routine and many specialty tests, though at much broader scale and as a partial substitute for hospital outreach.

TypeBroad incumbent
Description

Major U.S. national reference lab with extensive specialty/esoteric testing and integrated oncology offerings. Head-to-head competitor for hospital outreach and specialty send-out volumes, with greater commercial scale and payor leverage.

TypeDirect peer
Description

National esoteric reference laboratory offering specialty testing in transplant immunology, HLA typing, immunogenetics, and diagnostic immunology — the closest large-scale analog to KSL's transplant immunology and esoteric assay portfolio.

TypeDirect peer
Description

Oncology-focused diagnostics company with commercial specialty assays (e.g., Oncotype DX) sold to oncologists and cancer centers. Comparable in oncology diagnostics sales motion and in developing LDT/commercial assays from novel biomarkers.

TypeDirect peer
Description

Specialty oncology reference lab with a deep menu in hematologic malignancy FISH, cytogenetics, and molecular oncology. Most directly comparable to KSL's cytogenetics/FISH business and the same oncologist/cancer-center customer base.

TypeDirect peer
Description

Specialty reference lab historically strong in reproductive, oncology, and esoteric molecular testing. Comparable in offering mix (specialty reference lab serving health systems and clinicians) and in being a regional/specialty-focused competitor to the national incumbents.

TypeBroad incumbent
Description

Hospital-affiliated esoteric reference laboratory offering a deep specialty menu across immunology, genetics, and oncology with national specimen shipping. Comparable as a broad esoteric reference lab competing for the same specialty send-out volumes.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance10 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

KSL Diagnostics

Clinical Reference Laboratory Servicesksldx.com

KSL Diagnostics is a CAP-accredited, CLIA-certified reference laboratory in Buffalo, NY, providing specialized cytogenetic, molecular, and immunology diagnostic testing to healthcare providers, transplant programs, and physician practices across five US-licensed states.

What KSL Diagnostics does

KSL Diagnostics, Inc. is a privately held, CAP-accredited and CLIA-certified national reference laboratory headquartered in Buffalo, New York, operating as a wholly-owned subsidiary of KSL Biomedical, Inc. The company provides specialized clinical diagnostic testing across four service lines: oncology cytogenetics (FISH panels for AML, MDS, MPN, CLL, multiple myeloma, ALL, lymphoma, and triple-hit lymphoma, plus conventional karyotyping), diagnostic immunology (HNA, Fungitell®, hepatitis serologies, Sjögren's disease antibodies, and the proprietary COVID-19 Immune Index™), transplant immunology (HLA typing, antibody screening, and deceased/living donor evaluation with 4-hour STAT turnaround), and biochemical/molecular genetics (disaccharidases activity panel). The test menu is built on conventional molecular and cytogenetic platforms (FISH, real-time PCR, flow cytometry, Luminex, gel agglutination, ELISA) and the company holds clinical laboratory permits in New York, Pennsylvania, California, Maryland, and Rhode Island, plus ASHI accreditation and ISO 13485/15189 certifications for affiliated KSL Biomedical manufacturing and laboratory facilities.

The company generates revenue on a fee-for-service, per-test basis billed to healthcare providers under CPT codes (e.g., AML Panel 88271x16, 88275x8; HLA Antibody Screen 86832/86833), with prices not publicly disclosed. Its go-to-market is consultative, sales-led enterprise field sales targeting oncologists, hematologists, pathologists, cytogenetic laboratories, and solid-organ transplant programs, with named anchor relationships at Kaleida Health facilities and Erie County Medical Center. A second channel serves consumers directly through 4 permanent Western New York testing sites and a 25+ partner network of independent pharmacies and urgent care centers, used initially for COVID-19 testing and vaccination pop-ups (Walden Galleria, Rainbow Bridge) that delivered over 500,000 pandemic-era tests. KSL is the central laboratory for ImCare Biotech's FDA Breakthrough Device Designation Seravue® LC-SPIK hepatocellular carcinoma assay and is preparing LDT panel launches in 2026-2027, signaling a planned expansion into solid tumor diagnostics.

KSL Diagnostics firmographics

Firmographics
Name
KSL Diagnostics
Legal name
KSL Diagnostics, Inc.
Website
https://ksldx.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Short description
KSL Diagnostics is a CAP-accredited, CLIA-certified reference laboratory in Buffalo, NY, providing specialized cytogenetic, molecular, and immunology diagnostic testing to healthcare providers, transplant programs, and physician practices across five US-licensed states.
Ownership category
akta.pro rank

KSL Diagnostics industry classification

Industry
Product category
Clinical Reference Laboratory Services
NAICS
Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151), In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAFAMAJ
Reference & Esoteric Testing Laboratories
SECONDARYHLAAALAN
Laboratory Developed Tests (LDTs) & Specialized Clinical Lab Assays
SECONDARYHLAHAAAI
Genetic, Cytogenetic & Prenatal Screening IVD
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAGAEAB
Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAAALAI
Cytology & Histopathology Diagnostics (IHC, ISH, tissue-based assays)
SECONDARYHLAGADAA
Bioanalytical Testing (PK/ADA/NAb)

Keywords

  • Clinical reference laboratory
  • Cytogenetic diagnostic testing
  • Molecular diagnostic services
  • Transplant immunology testing
  • FISH probe panels

Where KSL Diagnostics is headquartered

Location

Headquarters

HQ city
Buffalo
HQ country
United States
HQ region
North America

Offices1 record

Markets served

KSL Diagnostics business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

  1. Clinical Laboratory Testing Services: Reference laboratory providing diagnostic testing services for oncology, cytogenetics, molecular diagnostics, diagnostic immunology, transplant immunology, and genetic testing. Revenue generated through billable laboratory tests ordered by healthcare providers.
  2. COVID-19 Testing Services: COVID-19 testing including RT-PCR (30-minute and 24-hour turnaround) and rapid antigen tests provided at testing sites and pop-up locations. Revenue generated through test fees, insurance billing, and government assistance programs.
  3. Specialized Diagnostic Panels: Comprehensive disease-specific testing panels (e.g., AML Panel, CLL Panel, MDS Panel) and individual FISH probes offered as discrete laboratory tests billed per CPT code

Pricing tiers

ModelBillingPrice
Transaction based/ take ratePay-as-you-goLaboratory diagnostic tests billed per test or panel

Go-to-market motion2 records

Distribution channels5 records

Marketing channels7 records

KSL Diagnostics product offering

Product offering

Core offering

KSL Diagnostics is a national reference laboratory providing clinical diagnostic testing services in cytogenetics (FISH panels for leukemia, lymphoma, and myeloma), molecular oncology, diagnostic immunology, transplant immunology (HLA typing and donor evaluation), biochemical/molecular genetics, and infectious disease (including its proprietary COVID-19 Immune Index™ antibody test). Tests are ordered by healthcare providers and delivered through a CAP-accredited, CLIA-certified laboratory operating 24/7 for STAT testing, with results delivered via the KSL Outreach® secure portal.

Product overview

KSL Diagnostics is a national reference laboratory offering integrated clinical diagnostic services across four main divisions: Oncology/Cytogenetics (FISH panels for AML, MDS, MPN, CLL, Multiple Myeloma, ALL, Lymphoma, and Triple Hit Lymphoma plus chromosome analysis), Diagnostic Immunology (HNA, Fungitell®, Hepatitis, Sjögren's Disease, and COVID-19 Immune Index™ testing), Transplant Immunology (HLA typing, antibody monitoring, and donor evaluation for solid organ transplantation), and Biochemical/Molecular Genetics (disaccharidases panel). The company operates as a CAP-accredited and CLIA-certified facility providing comprehensive testing menus across oncology, immunology, genetics, and infectious diseases. KSL also serves as the central laboratory for ImCare Biotech's LC-SPIK hepatocellular carcinoma Clinical Trial Assay. Testing services are supported by a secure reporting portal (KSL Outreach®) and the COVID-19 Immune Index™ for immunity assessment.

Differentiator

Problem solved

Functional benefit

Brands

  • COVID-19 Immune Index™: First-of-its-kind antibody test that detects immune response to COVID-19 and assesses risk of infection if subsequently exposed. Correlates COVID-19 virus neutralization against antibody levels.

Products and services

  • AML Panel Comprehensive FISH panel for Acute Myeloid Leukemia covering 8 genetic markers including t(15;17) PML/RARA, inv(16) CBFB, t(8;21) RUNX1T1/RUNX1, and key deletions and translocations; KSL guarantees 24-hour STAT results for PML/RARA. Ordered by hematologists, oncologists, and pathology groups for AML diagnosis, prognosis, and treatment guidance.
  • MDS Panel FISH panel for Myelodysplastic Syndromes covering del(5q)/monosomy 5, del(7q)/monosomy 7, del(20q)/monosomy 20, Trisomy 8, and 11q23.3 KMT2A. Used by hematologists and pathologists for MDS diagnosis and risk stratification.
  • MPN Panel FISH panel for Myeloproliferative Neoplasms detecting PDGFRB and FGFR1 rearrangements and the CML-associated t(9;22) BCR/ABL/ASS translocation. Used to support diagnosis and therapeutic targeting in MPN and CML.
  • CLL Panel FISH panel for Chronic Lymphocytic Leukemia covering 6q23.3 MYB, 11q23.3 ATM, Trisomy 12, t(11;14) CCND1/IGH, del(13q), and 17p13 TP53. Used by hematologists for CLL prognosis and treatment selection.
  • Multiple Myeloma (MM) Panel FISH panel for Multiple Myeloma using CD138+ plasma cell selection, covering CDKN2C/CKS1B, trisomies, RB1, IGH, and TP53 markers; includes an MM Reflex Panel for IgH rearrangement. Used for myeloma risk stratification and disease monitoring.
  • ALL Panel FISH panel for Acute Lymphoblastic Leukemia detecting 8q24.21 MYC, t(9;22) BCR/ABL1, 11q23.3 KMT2A, and 14q32.3 IGH rearrangements. Used to support ALL diagnosis, risk stratification, and targeted therapy decisions.
  • Lymphoma Panel FISH panel for lymphoma detection covering BCL6, MYC, CCND1/IGH, IGH, and IGH/BCL2 translocations. Used by pathologists and oncologists to classify lymphoma subtype.
  • Triple Hit Lymphoma FISH Panel Specialized FISH panel for high-grade B-cell lymphomas detecting concurrent rearrangements of MYC, BCL2, and BCL6 (double/triple-hit lymphomas) using 18q21.3 BCL2, 3q27 BCL6, and 8q24.21 MYC probes. Used for aggressive lymphoma classification and treatment planning.
  • Chromosome Analysis (Conventional Karyotype) Conventional cytogenetic karyotype analysis for hematopoietic malignancies using bone marrow or peripheral blood specimens to detect acquired chromosome abnormalities. Used by hematologists and oncologists alongside FISH panels.
  • Human Neutrophil Antibodies (HNA) Test Bead-based multiplex immunoassay detecting neutrophil antibodies associated with TRALI, SLE, RA, Myasthenia gravis, Felty's syndrome, and drug-induced neutropenia. Used by transfusion medicine services and immunologists.
  • Fungitell® (1,3)-Beta-D-Glucan Test Qualitative ELISA for invasive fungal infections including Candida, Aspergillus, and Pneumocystis, with an optional reflex to titer. Used by infectious disease and immunology clinicians.
  • Hepatitis D (Anti-HDV) Antibody Test Qualitative ELISA for Hepatitis D antibody detection for clinical workup of hepatitis D co-infection.
  • Hepatitis E IgG ELISA Qualitative ELISA for Hepatitis E IgG antibody detection used to evaluate prior exposure or immunity.
  • Tissue Specific Antibodies in Early Sjögren's Disease Diagnosis Immunoassay billed under PLA code 0522U for early detection of Sjögren's Disease-specific tissue antibodies, supporting autoimmune diagnosis and clinical research.
  • Disaccharidases Activity Panel Quantitative spectrophotometry assay of disaccharidase enzyme activity in small intestine tissue biopsies for diagnosis of gastrointestinal dysfunction and lactose intolerance.
  • Deceased Donor Evaluation HLA typing and evaluation for deceased organ donors using Real-Time PCR, Flow Cytometry, and Gel Agglutination, with STAT results within 4 hours of receipt. Used by solid-organ transplant programs.
  • Living Donor Evaluation Preliminary or final HLA typing for living organ donors, including lymphocyte crossmatch with intended recipients. Used by solid-organ and bone marrow transplant programs.
  • HLA Antibody Monitoring Luminex-based HLA antibody screening and identification for pre- and post-transplant monitoring, with reflex to single antigen testing. Used to detect sensitization and inform transplant timing.
  • Solid Organ Transplant Candidate Evaluation Comprehensive transplant candidate evaluation combining HLA typing and antibody monitoring using multiple methodologies. Used by transplant centers to evaluate candidates pre-transplant.
  • HLA Antibody Screen (Class I and Class II) Luminex-based screening for HLA Class I and Class II antibodies implicated in TRALI, transplant rejection, and bone marrow engraftment.
  • COVID-19 Immune Index™ First-of-its-kind antibody test that measures IgG titers and correlates results with plaque reduction neutralization test (PRNT) results to assess immune protection. Used by immunocompromised patients, at-risk populations, and clinicians to inform booster timing.
  • LC-SPIK (Seravue®) Hepatocellular Carcinoma Test Clinical Trial Assay for Hepatocellular Carcinoma using the Seravue® ELISA platform to detect the Liver Cancer-Secreted Serine Protease Inhibitor Kazal (LC-SPIK) biomarker, delivered in partnership with ImCare Biotech. Used by oncologists and clinical trial investigators for HCC diagnosis.

Quantifiable outcome

  • 100% virus neutralization at IgG levels of 20 and above in COVID-19 Immune Index testing
  • +2 more outcomes

Companies that use KSL Diagnostics

Customer profile

Named customers5 records

Segments5 records

Ideal customer profiles4 records

KSL Diagnostics technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

KSL Diagnostics partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core, secondary and minor.

  • ImCare BiotechcoreStrategic or Co-development Partner · 1 January 2025Partnership for hepatocellular carcinoma (HCC) diagnostics using LC-SPIK biomarker. KSL Diagnostics serves as central laboratory for Seravue® Validation Study (NCT06994130). KSL to launch LDT panels for HCC in 2026-2027. ImCare Biotech discovered and developed the LC-SPIK liver cancer biomarker.
  • State University of New York at BuffalocoreStrategic or Co-development Partner · 1 January 2024Dr. Lakshmanan Suresh serves as Clinical Professor at SUNY Buffalo. Multiple research collaborations with investigators throughout the world. KSL team members maintain academic affiliations and collaborative research programs.
  • University at Buffalo Jacobs School of Medicine and Biomedical SciencescoreStrategic or Co-development Partner · 1 May 2022Research partnership with UB on SARS-CoV-2 antibody studies leading to COVID-19 Immune Index™ development. Collaborated with Dr. Amy Jacobs on plaque reduction neutralization testing (PRNT) correlation studies using UB's Biosafety Level 3 containment facility. Study funded by UB Center for Advanced Technology in Big Data and Health Sciences (UB CAT).
  • University at Buffalo Center for Advanced Technology in Big Data and Health Sciences (UB CAT)coreStrategic or Co-development Partner · 1 May 2022UB CAT, a program of Empire State Development's Division of Science, Technology and Innovation (NYSTAR), supports university-industry collaborations. Funded research on COVID-19 antibody correlation studies and supported commercialization of COVID-19 Immune Index™.
  • Brighton-Eggert PharmacysecondaryChannel Partner/ Reseller/ Distributor · 1 November 2021WNY family-owned community pharmacy since 1968 administers COVID-19 vaccinations at KSL's Walden Galleria pop-up testing site. KSL provides testing infrastructure while pharmacy provides vaccination administration services.
  • Walden GalleriaminorChannel Partner/ Reseller/ Distributor · 1 November 2021Shopping mall location hosting KSL Diagnostics pop-up COVID-19 testing and vaccination site on second floor next to Macy's, serving holiday shoppers and Canadian travelers.
  • Rainbow Bridge Niagara FallsminorChannel Partner/ Reseller/ Distributor · 1 November 2021Mobile COVID-19 testing site at Rainbow Bridge corner (1st and Niagara Streets) serving cross-border travelers requiring PCR tests for Canadian entry.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

KSL Diagnostics competitors and assessment

Company assessment

Broad incumbents

  • Sonic Healthcare USA: International reference lab operator with a sizable U.S. footprint in clinical and specialty testing. Comparable as a multi-state reference lab competing in esoteric and specialty diagnostics.
  • Quest Diagnostics: Largest U.S. clinical laboratory with national logistics, broad specialty menu, and dominant payor contracts. Competes with KSL on routine and many specialty tests, though at much broader scale and as a partial substitute for hospital outreach.
  • Laboratory Corporation of America (Labcorp): Major U.S. national reference lab with extensive specialty/esoteric testing and integrated oncology offerings. Head-to-head competitor for hospital outreach and specialty send-out volumes, with greater commercial scale and payor leverage.
  • Mayo Clinic Laboratories: Hospital-affiliated esoteric reference laboratory offering a deep specialty menu across immunology, genetics, and oncology with national specimen shipping. Comparable as a broad esoteric reference lab competing for the same specialty send-out volumes.

Direct peers

  • Invitae: Genetic/molecular diagnostics company focused on hereditary cancer and broader genetic testing, serving oncologists and clinicians. Comparable to KSL's genetic testing and molecular oncology capabilities and customer overlap.
  • Natera: Molecular diagnostics company with specialty oncology and transplant-related testing (e.g., Signatera, Prospera). Comparable in its oncology-focused specialty menu and its positioning with cancer centers and transplant programs.
  • ARUP Laboratories: National esoteric reference laboratory offering specialty testing in transplant immunology, HLA typing, immunogenetics, and diagnostic immunology — the closest large-scale analog to KSL's transplant immunology and esoteric assay portfolio.
  • Exact Sciences (Genomic Health): Oncology-focused diagnostics company with commercial specialty assays (e.g., Oncotype DX) sold to oncologists and cancer centers. Comparable in oncology diagnostics sales motion and in developing LDT/commercial assays from novel biomarkers.
  • NeoGenomics Laboratories: Specialty oncology reference lab with a deep menu in hematologic malignancy FISH, cytogenetics, and molecular oncology. Most directly comparable to KSL's cytogenetics/FISH business and the same oncologist/cancer-center customer base.
  • BioReference Laboratories (OPKO Health): Specialty reference lab historically strong in reproductive, oncology, and esoteric molecular testing. Comparable in offering mix (specialty reference lab serving health systems and clinicians) and in being a regional/specialty-focused competitor to the national incumbents.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

KSL Diagnostics social profiles

Digital presence

KSL Diagnostics compliance and trust

Trust signal

Compliance10 records

KSL Diagnostics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

KSL Diagnostics leadership team

Management profile

Number of profiles

Profiles9 records

KSL Diagnostics subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

KSL Diagnostics funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

KSL Diagnostics M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about KSL Diagnostics

What does KSL Diagnostics do?

KSL Diagnostics is a national reference laboratory providing clinical diagnostic testing services in cytogenetics (FISH panels for leukemia, lymphoma, and myeloma), molecular oncology, diagnostic immunology, transplant immunology (HLA typing and donor evaluation), biochemical/molecular genetics, and infectious disease (including its proprietary COVID-19 Immune Index™ antibody test). Tests are ordered by healthcare providers and delivered through a CAP-accredited, CLIA-certified laboratory operating 24/7 for STAT testing, with results delivered via the KSL Outreach® secure portal.

Is KSL Diagnostics a public or private company?

KSL Diagnostics is a private company. It is classified as corporate owned and is currently operating.

When was KSL Diagnostics founded?

KSL Diagnostics was founded in 2018. It employs 11 to 50 people.

Where is KSL Diagnostics based?

KSL Diagnostics is headquartered in Buffalo, United States, in the North America region.

How does KSL Diagnostics make money?

Three revenue lines are on record. Clinical Laboratory Testing Services are the primary driver. The others are COVID-19 Testing Services and specialized Diagnostic Panels.

Who are KSL Diagnostics's main competitors?

Broad incumbents on record are Sonic Healthcare USA, Quest Diagnostics, Laboratory Corporation of America (Labcorp) and Mayo Clinic Laboratories. Direct peers are Invitae, Natera, ARUP Laboratories, Exact Sciences (Genomic Health), NeoGenomics Laboratories and BioReference Laboratories (OPKO Health).

Does KSL Diagnostics have an API?

No public API is recorded for KSL Diagnostics.

What industry is KSL Diagnostics in?

KSL Diagnostics's product category is Clinical Reference Laboratory Services. Its primary akta.pro industry code is HLAFAMAJ, Reference & Esoteric Testing Laboratories, with a secondary code of HLAAALAN, Laboratory Developed Tests (LDTs) & Specialized Clinical Lab Assays. Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals